CJC-1295 DAC & Ipamorelin Stack Dosage Protocol
GHRH analog (CJC-1295 DAC) + ghrelin-receptor GH secretagogue (Ipamorelin) — two separate research-only vials; the combination is not clinically validated.
Mix & measure CJC-1295 DAC + Ipamorelin · 5 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Dosing & Reconstitution Guide
Each peptide reconstituted in its own vial — CJC-1295 DAC dosed in mg, Ipamorelin in mcg
CJC-1295 DAC (5 mg Vial): Standard / Gradual Approach (2 mL = 2.5 mg/mL)
Reconstitute: Add 2.0 mL bacteriostatic water to one 5 mg vial → final concentration 2.5 mg/mL. Each full vial = 5 mg total.
Typical weekly total: 1–2 mg per week, given in 1–2 injections.
Easy measuring: At 2.5 mg/mL, 0.5 mg ≈ 20 units (0.2 mL) and 1 mg ≈ 40 units (0.4 mL) on a U-100 syringe.
Weeks 1–4
1–2 mg/week
0.5–1 mg
~0.2–0.4 mL (20–40 units)
1–2× per week
Why CJC-1295 DAC + Ipamorelin draws research interest
These are the directions researchers and the peptide community most often explore CJC-1295 DAC + Ipamorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
GH & IGF-1 support
The main draw: a GHRH analog paired with a GH secretagogue, both investigated for growth-hormone and IGF-1 release; neither is approved.
Body composition & lipolysis
Explored in research on how growth-hormone signaling relates to fat breakdown and lean-mass shifts; effects in humans remain investigational, not established.
Recovery & tissue repair
Investigated in preclinical work on how GH and IGF-1 pathways relate to connective-tissue and muscle repair; any recovery use is research-only and unproven.
Sleep & slow-wave sleep
Studied for the reported link between GH-secretagogue activity and slow-wave sleep architecture in early research; this remains investigational, not a clinical application.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
For example, at 2 mg/week split into 2 injections, each injection is ~1 mg (0.4 mL or ~40 units). A lower weekly total of 1 mg/week may require just one injection of 0.4 mL. Draw 2.0 mL of bacteriostatic water along the vial wall, swirl gently (do not shake), and refrigerate at 2–8 °C protected from light.
CJC-1295 DAC (5 mg Vial): Advanced / Aggressive Approach (1 mL = 5 mg/mL)
Reconstitute: Add 1.0 mL bacteriostatic water to one 5 mg vial → higher concentration 5 mg/mL. Typically used when aiming for ~3 mg/week in divided doses.
Easy measuring: At 5 mg/mL, 1 mg ≈ 20 units (0.2 mL) on a U-100 syringe — a smaller volume per injection.